Trials / Terminated
TerminatedNCT00566111
Ceftriaxone in the Management of Bipolar Depression
Modulation of Glutamatergic Neurotransmission in the Treatment of Bipolar Depression
- Status
- Terminated
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 5 (actual)
- Sponsor
- Yale University · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
We aim to study the efficacy of intravenous ceftriaxone in a four-week, inpatient, placebo-controlled, double-blind study, as an augmentation therapy in patients with bipolar disorder, currently depressed, who have failed to respond to conventional treatments.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ceftriaxone | 2g per day which will be administered IV via midline, 7 days a week for 4 weeks. |
| DRUG | Saline solution | Saline solution will be administered IV via midline, 7 days a week for 4 weeks. |
Timeline
- Start date
- 2007-09-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2007-12-03
- Last updated
- 2020-03-31
- Results posted
- 2016-10-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00566111. Inclusion in this directory is not an endorsement.